A phase 2 trial found the vaccines dramatically reduced the risk of the cancer returning in melanoma patients. A final, phase 3 trial has been launched and is being led by University College London Hospitals NHS Foundation Trust (UCLH) A nuclear fusion reaction has overcome two key barriers to operating in a ‘sweet spot’ needed for optimal power production.